Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404919 | 0.89 | MEN1 (0.40) | MEN1KMT2ACMA1ALDH1A1CHRM5 | |
| SCHEMBL13811863 | 0.85 | MEN1 (0.44) | MEN1KMT2ACMA1ALDH1A1CHRM5 | |
| SCHEMBL4397603 | 0.85 | MEN1 (0.44) | MEN1KMT2ACMA1ALDH1A1CHRM5 | |
| SCHEMBL4397334 | 0.78 | MEN1 (0.47) | MEN1KMT2ACMA1ALDH1A1CHRM5 | |
| SCHEMBL7616788 | 0.71 | NPSR1 (0.56) | MEN1KMT2AALDH1A1CHRM5MAPT | |
| SCHEMBL13821232 | 0.68 | MEN1 (0.39) | MEN1KMT2ACMA1ALDH1A1CHRM5 | |
| SCHEMBL1306136 | 0.68 | MMP9 (0.46) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL12229724 | 0.68 | NPSR1 (0.43) | MEN1KMT2ANPSR1 | |
| SCHEMBL16260330 | 0.66 | CA12 (0.41) | MEN1KMT2AMAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL14809312 | 0.65 | CA12 (0.41) | MEN1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | MEN1 4070/4885KMT2A 2002/4885CMA1 434/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | MEN1 3751/4885KMT2A 3334/4885CMA1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.